Why is Legend Biotech (LEGN) stock down today?

Legend Biotech shares dropped 13.41% to $19.24 — touching an intraday low of $18.64 — after the company announced that CEO Ying Huang has stepped down, effective immediately. Sudden, unplanned leadership departures at clinical-stage biotechs typically unsettle investors because the CEO is closely associated with the company's strategic direction, partner relationships, and ongoing clinical programs; without a clear succession story, uncertainty about execution rises and sellers tend to move first.

RBC Capital Markets cut its price target on Legend Biotech to $59 from $63 following the news, though it maintained its Outperform rating — meaning the analyst still views the stock favorably at a lower target. Separately, RBC noted that data from Legend's in vivo CAR-T cell therapy program (an experimental approach where gene-editing tools are delivered directly into the body rather than modifying cells outside it) validated the scientific approach, which one analyst cited as a reason for continued optimism around the company's under-development lymphoma asset.

The broader market offered little cushion: the S&P 500 (^GSPC) was essentially flat at +0.02% and the Nasdaq-100 (QQQ) was mildly negative at -0.32%, so the selloff in Legend Biotech was company-specific rather than a broad market-driven move. The stock's last quarterly revenue stood at $306.4 million, with a market cap of approximately $3.56 billion after today's decline.

The company's main commercial product, Carvykti, is a CAR-T cell therapy for multiple myeloma co-developed with Johnson & Johnson. Legend Biotech now trades well below the price targets maintained by at least one major analyst, reflecting the gap between near-term leadership uncertainty and the longer-term clinical pipeline story that remains intact per those analysts.